THE ROLE OF MICROBIOME IN CHRONIC RHINOSINUSITIS: IMPLICATIONS FOR PERSONALIZED TREARTMENT

Dr Rajeev Kumar Gupta1, Dr. Haritej Anand Khirawari2, Dr. Nitin Chauhan3, Dr Mohan Bhatnagar*4

1Associate Professor Department of OTO-RHINOLARYNGOLOGY K. D. Medical College, Hospital & Research Center, Mathura (UP)

2Assistant Professor Department of General Medicine K. D. Medical College, Hospital & Research Center, Mathura (UP)

3Associate Professor Department of General Medicine K. D. Medical College, Hospital & Research Center, Mathura (UP)

4Assistant Professor Department of OTO-RHINOLARYNGOLOGY K. D. Medical College, Hospital & Research Center, Mathura (UP)

Corresponding Author

Dr Mohan Bhatnagar

Assistant Professor Department of OTO-RHINOLARYNGOLOGY K. D. Medical College, Hospital & Research Center, Mathura (UP)

ABSTRACT

Chronic rhinosinusitis (CRS) is a long-standing inflammation of nasal and sinus mucosa, which negatively impacts patient’s quality of life. The recent research emphasize the central position of the microbiome in CRS with focus on microbial dysbiosis, meaning an upheaval of the normal bacterial flora, which erroneously fuels immune system chaos and inflammation. In CRS, pathogens like Staphylococcus aureus and Pseudomonas aeruginosa are found that replace normal flora and cause chronic symptoms. The current review discusses how bacterial diversity and immune reactions relate to CRS pathophysiology. It also assesses anti Microbiome Therapy, which includes Probiotics antibiotics, and Fecal Microbiota Transplant that has promising role in modifying microbial disturbances and enhancing patient prognosis. Although these developments, challenges like inconsistency in microbiome data and problems in identifying causal bacteria stays.

Due to accurate and efficient metagenomics, molecular diagnosis, and personalized on-targeted therapy and gene therapy in the future, there will be better therapeutic strategy and quality of life in patients with CRS.

Keywords: *Chronic Rhinosinusitis, Microbiome, Dysbiosis, Bacterial Populations, Immune Response, Inflammation, Staphylococcus aureus, Pseudomonas aeruginosa, Probiotics, Antibiotics, Microbiota Transplantation, Personalized Treatment, Microbial Diversity, Immune Modulation, Targeted Therapies, Precision Medicine*.

Introduction

CRS is a long-term inflammation of the nasal and sinus linings that has a major effect on patients' well-being due to constantly. While the emergence of the concept of microbiome dysbiosis is relative, its link with the formation of CRS is already intensively studied, a decrease in microbial diversity and pathogenic dominance enhance immune dysfunction and chronic inflammation. The knowledge of the microbiome's effects opens the door for advancing the course of therapy. This work emphasizes understanding the primary and secondary bacterial composition in CRS, deciphering the relationship between microbiota, immunity, and CRS, and appraising the precision approaches based on the microbiota recognition that can revolutionize future treatment of CRS based on its roots.

Literature review

Bacterial Diversity in CRS

According to Cope *et al*.2017, This research by the authors found that deadly long-term sinus problems change how germs normally live in the sinuses. Studies indicate that microbes in CRS patients differ from typical microbiota and have specific patterns of growth that make them work differently. CRS patients' noses have a lot of harmless PMN and SA germs, while their microbial variety plummets. The bacterial count changes the immune response changes, which worsens CRS conditions (Cope *et al*.2017). The study identify that how CRS groups differ based on which bacteria grow. Each group responds differently to bacteria through distinct body reactions during their disease flares. Knowing how these microbial changes happen is important for making unique treatments that target the microbiome to help people with CRS get better results.



Figure 1: CRS patients and their microbiota

(Source: Cope *et al*.2017)

Microbiome-Immunity Interaction

According to van der Meulen *et al*.2016, It discusses in this study how the microbiome controls the immune system's response in CRS by studying what goes wrong. During the composition of microbiota changes, this study shows it harms immune balance, making immune function abnormal. Certain bacteria that cause harm damage the skin links between cells, make cells act through TLRs, and cause immune system chemicals to form, leading to inflammation. Changes in gut bacteria make the immune system react too strongly and keep inflammation going in CRS. The research found that modifying the body's natural bacteria could both enhance and decrease immune system disorders all over the body (van der Meulen *et al*.2016). These results indicate that the microbiome works as both a trigger for immune system activation and a possible place for treatment in CRS patients, and they help us find ways to personalize treatment plans for these patients.



Figure 2: The sinuses of healthy individuals

(Source: https://www.mdpi.com/2076-0817/14/1/14)

Advanced in Targeted Therapies

According to Rooks, 2016, The study shows how gut treatments can help correct bacterial imbalances linked to colitis, which gives us ideas to apply to CRS control. The research shows how to fix a bacterial imbalance by giving probiotics, prebiotics, or antibiotics, both to restore well-being and reduce swelling. Bugs Lactobacillus and Bifidobacterium kill bad bacteria in the body while helping the immune system work better. Just like prebiotics, they aid the growth of specific helpful microbes that help keep the mucosal barrier healthy. Based on the research, doctors could help CRS patients by fixing their nose's normal microbiome to ease inflammation and give them better results (Rooks, 2016). The research looks at how bacteriotherapy with microbiota transplantation may create customized ways to treat people. By showing that fixing dysbiosis with the right microbiome treatments helps CRS, the author proves their value for coming up with more specific treatments for inflammatory diseases.

Methods

Data Collection

This study use the secondary research methodology to collect the data on microbiome from published articles on CRS between 2010 and 2018. Several databases that is use in the search included; peer-reviewed databases like PubMed and Scopus, and global search engine, the Google scholar. These are chronic rhinosinusitis, microbiome, bacterial diversity, immune response, and microbiome-based therapies. The eligibility criteria were concerned with bacterial abundance, immune response, microbial shifts interventions in CRS and relevant studies published in peer-reviewed journals only (Cervin, 2018). The obtained details for analysis, with a focus on 16S rRNA sequencing or metagenomics methods.

These data included information about bacterial richness and composition, pathogenic species, immune response, and treatment with probiotics, antibiotics and microbiota transplantation. To be included in the analysis, only papers that provided clear method descriptions, numerical outcomes, and statistical significance of findings is reviewed. Papers and reviews reporting exclusively Non-Animal Models, or reporting on other non-housed microbiomes is also exclude.

The gathered information is divide according to themes including bacterial loads in CRS patients versus healthy individuals, microbial profiles changes in relation to immunopathology, and microbiome interventions in clinical trials (Gurrola and Borish 2017). This approach allowed a thorough coverage of key findings and provided the understanding of the microbiome in CRS development and in the treatments.

Techniques

Microbial Sequencing Methods

Bacterial populations in CRS were identified by microbial sequencing techniques especially 16S rRNA sequencing. This technique enables the identification of bacterial taxa and the estimation of microbial diversity by amplifying and sequencing the highly conserved 16S rRNA gene. Sequencing of metagenomic samples allowed for obtaining the data about the functional genetics of microbial community and recognizing the bacterial species with their metabolic functions (Jervis Bardy, and Psaltis 2016). These approaches helped to identify the shift of microbes in the CRS patient group in comparison with healthy individuals and show dysbiosis. Sequence data for microbial communities were processed with CRS details available to enhance the level of accuracy for deciphering pathogenic and commensal bacterial strains.

Immune Response Profiling

The dominant method for bringing microbiome data from other studies was using 16S ribosomal RNA (rRNA) sequencing. Bacterial species in CRS patient sinuses can both identify and count with this modern research method. With its focus on specific DNA regions shared across bacteria, the system detects both well-known and difficult-to-find bacteria to show broad plant health (Kim, and Cho, 2017). The studies using metagenomics sequencing helped to discover the activities in the microbiome, showing how it affects CRS disease development.

The microbiome based therapy

The researchers considered clinical studies that explore how different microbiome treatments work with probiotics, antibiotics, and microbial transplants to better understand their potential for CRS management (Ghogomu, and Kern 2017). It combined the results about how changes in microbes, less inflammation, and better symptoms can help guide doctors in choosing the right treatments for patients with CRS.

Result

Study of bacterial populations



Figure 3: Respiratory health affected by homeostasis

(Source: https://www.frontiersin.org)

The microbiome study found special types of bacteria that consistently show up in people with CRS. In patients with CRS, two common bacteria (Staphylococcus aureus and Pseudomonas aeruginosa) showed higher numbers compared to healthy people, with S. aureus sometimes-causing inflammation and tissue damage. Those two healthy types of bacteria is identify to be present in more limited numbers in people with CRS (Hoggard *et al*.2017). The sinuses in CRS patients show signs of microbial imbalance, with a decreased number of different bacteria and too many harmful species compared to healthy bacteria, leading to problems keeping the sinuses healthy.

Connection to immune response

This research showed that two types of bacteria, Staphylococcus aureus and Pseudomonas aeruginosa, appeared much more often in people with CRS than in healthy controls. The study found higher levels of S. aureus and P. aeruginosa in CRS patients compared to healthy persons, with studies showing that S. aureus boosts inflammation that harms nasal tissues (Cope *et al*.2016). In people with CRS, the numbers of good bacteria like Lactobacillus and Bifidobacterium are much lower than normal. The sinuses of CRS patients had disrupted microbial balance, with both harmful and helpful bacteria, instead of their normal mix.



Figure 4: Microbiome of Unilateral Chronic Rhinosinusitis

(Source: https://www.mdpi.com/1660-4601/18/18/9878)

The develop process of targeted therapies

The clinical trials in CRS looked at how therapies targeting the microbiome helped relieve symptoms. When given Lactobacillus and Bifidobacterium in probiotic treatments, they helped bring back normal levels of bacteria while lowering the inflammation. People who used antibiotics saw improvements when their sinuses had less Staphylococcus aureus and Pseudomonas aeruginosa, and their symptoms got better (De Rudder *et al.*2018). The studies showed that putting back healthy bacteria helped the sinuses recover their normal balance of germs while also working better with the body's immune system. The bugs live in people's sinuses might be a good way to create better treatments just for them since it can help fix the microbial problems that cause their conditions.

Discussion

The study shows that certain bacteria types, like Staphylococcus aureus and Pseudomonas aeruginosa, make CRS worse by making the immune system overreact and misbehave. By adding good bugs like probiotics and killing harmful bacteria with targeted antibiotics, it can fix the body's immune reaction and correct health imbalances (Lee *et al.*2018). There are many small progress has been made, but researchers are concern because it is tough to identify specific bacteria causing CRS. It cannot effectively create standard treatment plans because the data in different studies does not connect. Although microbiome interventions face obstacles, the findings show they could help fight CRS diseases better if it keep studying and testing treatments.

Future Directions

It is identify that CRS degrades when specific bacteria such as Staphylococcus aureus and Pseudomonas aeruginosa overstimulate the immune system and cause it to act incorrectly. When it use probiotics to introduce helpful bacteria and target the right antibiotics to eliminate harmful ones, it can restore how the immune system functions properly and bring the body back to health. It made some small improvements, but researchers struggle because they cannot connect specific bacteria to CRS and studies keep giving different results (Kucuksezer *et al.*2018). Difficulties arise in building good treatment guidelines because data from different studies differs. The research shows that studying and testing new ways to balance the microbiome can help conquer CRS diseases better if it keeps working at it.

Conclusion

Chronic rhinosinusitis keeps being tough to treat because the main things occur that the immune system does not work right, and our normal body bugs get thrown off balance. This study shows how reduced microbiome diversity and rising staph and pseudomonas infections make CRS harder to cure. When these microbial disturbances exist, they keep inflammation going long-term, making it difficult for the body's immune system to work well. It need to learn how these interactions work in order to find new and more successful ways of treating CRS.

Researchers are developing new ways involving probiotics, antibiotics, and microbiota transfers to improve the bacterial makeup, control immune cells, and do better in treating patients' conditions. Microbiome data is hard to compare, finding the exact bacteria causing CRS is hard, and study methods are not uniform, which makes it challenging to use microbiome therapies widely in clinical practice.

The modern testing methods metagenomics, host-microbe research, and host-microbiome research to understand how microbes connect with CRS disease. By these medical information from microbiome studies and personalized care technologies, the doctors can create treatment plans designed only for each person's microbiome treatment. The studies on investigating how CRS and the microbiome interact will expose new possibilities to treat CRS in ways that help people feel better and appreciate healthier lives.

Reference List

Journal

Cervin, A.U., 2018. The potential for topical probiotic treatment of chronic rhinosinusitis, a personal perspective. Frontiers in cellular and infection microbiology, 7, p.530.

Cope, E.K., Goldberg, A.N., Pletcher, S.D. and Lynch, S.V., 2016, December. A chronic rhinosinusitis–derived isolate of Pseudomonas aeruginosa induces acute and pervasive effects on the murine upper airway microbiome and host immune response. In International Forum of Allergy & Rhinology (Vol. 6, No. 12, pp. 1229-1237).

Cope, E.K., Goldberg, A.N., Pletcher, S.D. and Lynch, S.V., 2017. Compositionally and functionally distinct sinus microbiota in chronic rhinosinusitis patients have immunological and clinically divergent consequences. Microbiome, 5, pp.1-16.

De Rudder, C., Calatayud Arroyo, M., Lebeer, S. and Van de Wiele, T., 2018. Modelling upper respiratory tract diseases: getting grips on host-microbe interactions in chronic rhinosinusitis using in vitro technologies. Microbiome, 6, pp.1-13.

Ghogomu, N. and Kern, R., 2017. Chronic rhinosinusitis: the rationale for current treatments. Expert review of clinical immunology, 13(3), pp.259-270.

Gurrola II, J. and Borish, L., 2017. Chronic rhinosinusitis: endotypes, biomarkers, and treatment response. Journal of Allergy and Clinical Immunology, 140(6), pp.1499-1508.

Hoggard, M., Wagner Mackenzie, B., Jain, R., Taylor, M.W., Biswas, K. and Douglas, R.G., 2017. Chronic rhinosinusitis and the evolving understanding of microbial ecology in chronic inflammatory mucosal disease. Clinical microbiology reviews, 30(1), pp.321-348.

Jervis Bardy, J. and Psaltis, A.J., 2016. Next generation sequencing and the microbiome of chronic rhinosinusitis: a primer for clinicians and review of current research, its limitations, and future directions. Annals of Otology, Rhinology & Laryngology, 125(8), pp.613-621.

Kim, D.W. and Cho, S.H., 2017. Emerging endotypes of chronic rhinosinusitis and its application to precision medicine. Allergy, asthma & immunology research, 9(4), pp.299-306.

Kucuksezer, U.C., Ozdemir, C., Akdis, M. and Akdis, C.A., 2018. Chronic rhinosinusitis: pathogenesis, therapy options, and more. Expert opinion on pharmacotherapy, 19(16), pp.1805-1815.

Lee, K., Pletcher, S.D., Lynch, S.V., Goldberg, A.N. and Cope, E.K., 2018. Heterogeneity of microbiota dysbiosis in chronic rhinosinusitis: potential clinical implications and microbial community mechanisms contributing to sinonasal inflammation. Frontiers in cellular and infection microbiology, 8, p.168.

Rooks, M.G., 2016. Microbiome-Targeted Interventions for Colitis-Associated Bacteria (Doctoral dissertation).

van der Meulen, T.A., Harmsen, H.J., Bootsma, H., Spijkervet, F.K., Kroese, F.G. and Vissink, A., 2016. The microbiome–systemic diseases connection. Oral diseases, 22(8), pp.719-734.